BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240516T090000
DTEND;TZID=Europe/Brussels:20240516T180000
DTSTAMP:20260808T013912
CREATED:20240118T152254Z
LAST-MODIFIED:20240118T152720Z
UID:7279-1715850000-1715882400@www.europabio.org
SUMMARY:Knowledge for Growth
DESCRIPTION:Get ready for the touchdown of Europe’s finest life sciences conference\, Knowledge for Growth\, on May 16\, 2024\, in the vibrant city of Antwerp\, Belgium!Elevate your network by rubbing shoulders with decision-makers from biotech\, pharma\, and MedTech\, alongside investors\, universities\, cutting-edge research institutes\, policymakers\, and competence providers. Join over 1000 life sciences trailblazers representing 500+ companies & organizations! Uncover the future with our riveting programme\, delivering key insights into the global and regional life sciences landscape. Engage in dynamic B2B partnering\, explore groundbreaking innovations at the trade fair\, and seize endless networking opportunities.Ready to be part of the life sciences revolution? Secure your spot now here! #KnowledgeForGrowth #KFG2024  \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/knowledge-for-growth-2/
LOCATION:Flanders Meeting & Convention Center Antwerp
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240514T200000
DTEND;TZID=Europe/Brussels:20240515T180000
DTSTAMP:20260808T013912
CREATED:20240311T142703Z
LAST-MODIFIED:20240311T142744Z
UID:7536-1715716800-1715796000@www.europabio.org
SUMMARY:AseBio Investor Day
DESCRIPTION:We are thrilled to announce that AseBio will hold the fifth edition of the AseBio Investor Day at the gorgeous Kursaal conference center in San Sebastián (Spain) on the 15th of May. The AseBio Investor Day is a forum that aims to connect the Spanish biotechnology industry with national and international investors. \n\n\n\nSince its first edition (Barcelona\, 2017)\, the event has attracted national and international investors\, contributing to give visibility to the national biotechnology industry. AseBio Investor Day also fosters networking between investors from Spain and the rest of the world. \n\n\n\nAseBio Investor Day includes a program of round tables where relevant topics on investment and finance will be addressed\, one-to-one meetings and startup pitch presentations. There will also be socials where you can meet your peers and biotech entrepreneurs. \n\n\n\nMeeting Spanish biotechnology is an opportunity to access new deal flow opportunities. Spain is the 9th largest originator of knowledge in biotechnology by number of papers. As of 2023 there were about 900 firms fully dedicated to biotechnology and 270 firms partially dedicated to biotechnology. In 2022 the sector attracted €142 million. \n\n\n\nIn our last edition more than 260 attendees participated in Investor Day and more than 330 one-to-one meetings were held through our matchmaking tool. \n\n\n\nSan Sebastián is a beautiful coastal town in the Spanish Basque Country. The city boasts stunning beaches\, a rich gastronomical tradition with one to the highest densities of Michelin star restaurants in the world\, splendid architecture and a thriving cultural life. The event will take place immediately after BioEquity\, which this year will be held on May 14 and May 15 in the same venue. \n\n\n\nIf you are planning to attend BioEquity why not extend your stay one more day and join us for an opportunity to meet Spanish biotechnology. Investors are cordially invited to participate in the AseBio Investor Day 2024. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/asebio-investor-day/
LOCATION:Kursaal Zurriola Hiribidea\, 1 20002 Donostia\, Guipuzkoa (Spain)
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Healthcare.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260808T013912
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240229T090000
DTEND;TZID=Europe/Brussels:20240301T170000
DTSTAMP:20260808T013912
CREATED:20240214T085311Z
LAST-MODIFIED:20240214T100345Z
UID:7415-1709197200-1709312400@www.europabio.org
SUMMARY:International Congress on Rare Diseases and Orphan Drugs 2024
DESCRIPTION:Navigating the Uncharted: Advancements\, Collaborations\, and Hope in Rare Diseases \n\n\n\nSupported by EuropaBio \n\n\n\n \n\n\n\nAbout the event: \n\n\n\nEmbrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress\, where innovation\, collaboration\, and hope converge! \n\n\n\nThe International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG)\, member of EURORDIS-Rare Diseases Europe and Boussias Events. \n\n\n\nFollowing the success of the previous years and having advanced the policy agenda on both a national and international level\, the Organizing Committee – consisting of Rare Diseases Greece (RDG)\, the 30-member umbrella organization that represents the country’s rare disease community\, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases. \n\n\n\nAttendance details: \n\n\n\nThursday\, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday\, 01.03.2024 (Digital) \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nFind out more here
URL:https://www.europabio.org/event/international-congress-on-rare-diseases-and-orphan-drugs-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banner-International-Congress-on-Rare-Diseases-Orphan-Drugs-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240214T080000
DTEND;TZID=Europe/Brussels:20240214T170000
DTSTAMP:20260808T013912
CREATED:20240130T125205Z
LAST-MODIFIED:20240130T125207Z
UID:7333-1707897600-1707930000@www.europabio.org
SUMMARY:Europe Rare Disease Summit 2024
DESCRIPTION:How to improve and learn about Government Plans\, Access & Financing\, Clinical Research and Innovation\, Artificial Intelligence and Data\, and Social & Patient. \n\n\n\nJoin our very own Healthcare Policy Senior Manager\, Adrien Samson in Madrid where he will be speaking in the panel “Innovation\, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00. \n\n\n\n \n\n\n\nWe are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit\, set to take place in February. Joining forces from all corners of Europe\, this prestigious event brings together leading researchers\, healthcare professionals\, patient advocates\, policymakers\, industry experts\, and rare disease patients and families. \n\n\n\nThe summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together\, we can accelerate research\, enhance patient care\, and improve outcomes\, offering a brighter future for those affected by rare diseases. \n\n\n\nKey Objectives: \n\n\n\nEmpowering Patients: Putting patients at the heart of our efforts\, we strive to enhance their access to quality care and support\, while advocating for their rights and unique challenges. \n\n\n\nAdvancing Research: Renowned scientists will present groundbreaking discoveries\, fostering cross-disciplinary collaboration to propel rare disease research forward. \n\n\n\nBuilding Collaborative Networks: A platform for stakeholders to connect\, exchange ideas\, and form strategic partnerships\, bridging gaps in research\, treatment\, and support. \n\n\n\nInfluencing Policy: By engaging policymakers\, we seek to drive positive changes and better support the rare disease community. \n\n\n\nEngaging Program Highlights: Expect a dynamic lineup of keynote speeches\, interactive workshops\, panel discussions and networking opportunities. Share experiences\, learn from experts\, and inspire change. \n\n\n\nLocation and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th. \n\n\n\nWho will Attend: \n\n\n\nRare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students
URL:https://www.europabio.org/event/europe-rare-disease-summit-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banner-ERDS-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260808T013912
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231106T153000
DTEND;TZID=Europe/Brussels:20231106T163000
DTSTAMP:20260808T013912
CREATED:20231013T105949Z
LAST-MODIFIED:20231013T105951Z
UID:6985-1699284600-1699288200@www.europabio.org
SUMMARY:BIO Europe 2023
DESCRIPTION:The European Pharmaceutical Legislation – Will it keep the light on for biotech in Europe? \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 6th of November in Munich for her panel discussing what the legislation brings\, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version\, that it works for both\, the biotech ecosystem\, maintaining innovation pipelines\, and patients.
URL:https://www.europabio.org/event/bio-europe-2023/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-113155.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231101T080000
DTEND;TZID=Europe/Brussels:20231102T170000
DTSTAMP:20260808T013912
CREATED:20231013T082312Z
LAST-MODIFIED:20231013T082314Z
UID:6977-1698825600-1698944400@www.europabio.org
SUMMARY:World Orphan Drug Congress
DESCRIPTION:The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 1st of November for her Keynote Panel: How to navigate the new legislation to enable orphan drug developers to stay innovative and profitable in Europe. \n\n\n\nAs well as on the 2nd on November for her Panel: How to enable SME’s to obtain greater market access.
URL:https://www.europabio.org/event/world-orphan-drug-congress/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-101414.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231023T124000
DTEND;TZID=Europe/Brussels:20231023T141000
DTSTAMP:20260808T013912
CREATED:20231012T114428Z
LAST-MODIFIED:20231012T115640Z
UID:6973-1698064800-1698070200@www.europabio.org
SUMMARY:TOPRA Symposium 2023: advancing global healthcare together
DESCRIPTION:Session: Update on EU new regulatory legislation and a view from different angles \n\n\n\nJoin our very own Valentin Plouchard who will be speaking at the TOPRA Annual Symposium in Lisbon on the 23rd of October.
URL:https://www.europabio.org/event/topra-symposium-2023-advancing-global-healthcare-together/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-12-133359.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260808T013912
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230929T100000
DTEND;TZID=Europe/Brussels:20230930T190000
DTSTAMP:20260808T013912
CREATED:20230320T153927Z
LAST-MODIFIED:20230320T160626Z
UID:6049-1695981600-1696100400@www.europabio.org
SUMMARY:International Forum on Industrial Biotechnology and Bioeconomy (IFIB)
DESCRIPTION:NETWORKING AND PARTNERSHIPS IN BIOECONOMY AREA \n\n\n\nIFIB – International Forum on Industrial Biotechnology and Bioeconomy aims at strengthening the bioeconomy network in the Euro-Mediterranean area and to promote partnerships. The focus of the Forum is biotechnology\, as provider of new resources for industries. \n\n\n\nIt is organized into round-tables and sessions devoted to specific sub-sectors of industrial biotechnology: bio-based industries\, agro-food\, energy\, environment policies on industrial biotech and bioeconomy\, involving international speakers coming from key sector’s players. \n\n\n\nEdition 2023 > 29/30 September Bari \n\n\n\n\nMore information
URL:https://www.europabio.org/event/international-forum-on-industrial-biotechnology-and-bioeconomy-ifib/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230926T100000
DTEND;TZID=Europe/Brussels:20230928T190000
DTSTAMP:20260808T013912
CREATED:20230320T145053Z
LAST-MODIFIED:20230320T145327Z
UID:6038-1695722400-1695927600@www.europabio.org
SUMMARY:BIOSPAIN 2023
DESCRIPTION:BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. \n\n\n\nThis year\, BIOSPAIN goes back to Barcelona\, the main biotech cluster in Spain and one of the most dynamic cities in the world. \n\n\n\nThe event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center\, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park\, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/biospain-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230920T080000
DTEND;TZID=Europe/Brussels:20230921T170000
DTSTAMP:20260808T013912
CREATED:20230615T070358Z
LAST-MODIFIED:20230615T070523Z
UID:6387-1695196800-1695315600@www.europabio.org
SUMMARY:Life Sciences Baltics as a contributor to Lithuania’s innovation ecosystem
DESCRIPTION:Life sciences in Lithuania have been a priority for the government for over a decade. Accelerating faster than almost anywhere else in Europe\, the sector aims to contribute 5% to Lithuania’s GDP by 2030. The close cooperation between actors of the ecosystem is one of the reason for success.   \n\n\n\nCreative collaboration takes place in Lithuania’s innovation ecosystem in a variety of ways\, including events\, cross-promotion\, and sharing of resources. The leading life sciences Baltics event in the region – Life Sciences Baltics – is one of the best examples of these collaborations. \n\n\n\nSince its initiation in 2012\, the forum has aimed to create as many opportunities as it is possible for deeper cooperation between the growing life sciences ecosystems in the Baltics and international partners. \n\n\n\nHeld every two years\, the forum has grown from a 300-person assembly to a community of up to 800 key participants from around 40 countries: corporate CEOs\, startup founders\, tech scouts\, investors\, researchers. It is the largest life sciences event in the Eastern and Central Europe. \n\n\n\nThe event will take place in the Lithuania’s capital city of Vilnius on September 20-21. The pre-registration is already open for participants and exhibitors. \n\n\n\nWhether there is a need to kick off the project\, generate leads\, or engage in valuable partnerships\, Life Sciences Baltics offers a diverse range of interactions for its participants: international conference\, exhibition\, networking spaces\, pitch challenge for startups. \n\n\n\nIt also hosts business delegations and offers an opportunity for side visits to Lithuania’s organizations and institutions. \n\n\n\nThe program of the international conference is divided into sessions with the most trending topics worldwide that are also breakthrough areas in the Baltic countries: gene editing\, CRISPR diagnostics\, AI and digital health innovations\, nanomedicine\, microbiome\, reinvention of clinical trials\, digital biomarkers and many more. \n\n\n\nMany big names have attended Life Sciences Baltics\, among them Thermo Fisher Baltics\, Johnson&Johnson\, Clarivate\, Novartis\, Abbvie\, AstraZeneca\, and others. Nobel prize winners Richard Henderson\, Brian Kobilka\, Dan Shechtman\, CRISPR pioneer Prof. Dr Virginijus Šikšnys were among top conference speakers. \n\n\n\nThe event will keep tabs on the fastest growing startups in the region\, but only 10 hand-picked startups will have an opportunity to showcase who they are in front of a panel of investors. \n\n\n\nThe event is organized by Innovation Agency Lithuania\, an official public agency responsible for the Lithuanian innovation ecosystem and is supported by Lithuania’s local ecosystem actors – Lithuanian biotechnology association\, universities\, hospitals\, business angels and Lithuania’s life sciences enthusiasts.  \n\n\n\nThe Baltics\, and Lithuania in particular\, – the next big thing in life sciences  \n\n\n\nLife Sciences Baltics make it possible to assess the attractiveness of the Baltic countries in close-up – Estonia\, Latvia and Lithuania show their distinct\, but strong potential in the sector. \n\n\n\nThree Baltic countries are particularly seeing a growth in life sciences startups. While average funding per startup is decreasing globally\, it’s increasing in the region.  Lithuania attracts growing VC interest into global solutions produced by local entrepreneurs and scientists. \n\n\n\nFocused on nurturing the next generation of talents\, the local life sciences enterprises in the Baltics excel at creativity and entrepreneurship. In 2021 alone\, Lithuania’s life sciences sector grew by almost 87% and generated revenues of 2 billion euros. \n\n\n\n90% of the output of Lithuania’s life sciences are exported to more than 100 countries worldwide. Lithuanian-made medical and pharmaceutical equipment and other products are trusted by customers in the USA\, Germany\, France\, and elsewhere. \n\n\n\nOne of the most prominent players in Lithuania is Thermo Fisher Scientific Baltics\, which has stimulated the development of Lithuania’s industry during the last decade. This company\, along with other international players in the market\, work with local actors for various R&D projects and supply chain. \n\n\n\n\nFor more details
URL:https://www.europabio.org/event/life-sciences-baltics-as-a-contributor-to-lithuanias-innovation-ecosystem/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230704T100000
DTEND;TZID=Europe/Brussels:20230704T170000
DTSTAMP:20260808T013912
CREATED:20230614T151559Z
LAST-MODIFIED:20230614T151749Z
UID:6377-1688464800-1688490000@www.europabio.org
SUMMARY:Industrial Biotechnologies Day
DESCRIPTION:CEFIC Specialty Chemicals sector groups EFCG\, Biochem Europe and EFG\, together with SICOS\, the French industry association for Fine Chemicals and Biotech\, will jointly hold their first in-person Industrial Biotechnologies Day on July 4th\, 2023 in Brussels. \n\n\n\nSpecialists from the industry\, EU policy makers\, and civil society will come together across four panels to dive into topics such as: \n\n\n\n\nEuropean policies shaping the biotech landscape – what is needed to unleash its full potential?\n\n\n\nEuropean regulatory frameworks – an obstacle to innovation?\n\n\n\nFeedstocks and industrial capacities – what is the role of energy costs?\n\n\n\nNew technologies and future breakthroughs – what to expect and what’s at stake?\n\n\n\n\nConfirmed Speakers: \n\n\n\n\nHans Ingels\, European Commission – Directorate-General for Internal Market\, Industry\, Entrepreneurship and SMEs\n\n\n\nLudo Diels\, Flemish Institute for Technological Research (VITO)\n\n\n\nVincent Touraille\, Sicos\n\n\n\nKarel De Winter\, Bio Base Europe Pilot Plant\n\n\n\nMarcello Buson\, Olon SpA\n\n\n\nFrédéric Van Gansberghe\, Futerro\n\n\n\nClaire Skentelberry\, Europabio\n\n\n\nChristian Le Roux\, Group M21\n\n\n\nHarald Ruissenaars\, Corbion\n\n\n\nEric Bierny\, Galactic\n\n\n\nNicolas Martin\, Metex\n\n\n\nThomas Canova\, Solvay\n\n\n\nJulien Honoré\, Roquette\n\n\n\nJuliette Martin\, Seqens\n\n\n\nGwenaël Servant\, Abolis\n\n\n\n\n\nMore details
URL:https://www.europabio.org/event/industrial-biotechnologies-day/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230630T124500
DTEND;TZID=Europe/Brussels:20230630T124500
DTSTAMP:20260808T013912
CREATED:20230321T210403Z
LAST-MODIFIED:20230321T210405Z
UID:6074-1688129100-1688129100@www.europabio.org
SUMMARY:DUTCH BIOTECH EVENT 2023
DESCRIPTION:Join us to celebrate the power of biotech at the Dutch Biotech Event 2023! \n\n\n\nAbout HollandBIO’s Dutch Biotech Event \n\n\n\nThe program features inspiring talks by keynote speakers on biotech and entrepreneurship\, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition\, there will be plenty of opportunities for networking during the break\, drinks and vegetarian BBQ. \n\n\n\nWho can join Dutch Biotech Event? \n\n\n\nThe Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295\,- p.p.)\, with a maximum of 2 delegates per organization. \n\n\n\nWe invite non-member startups to consider a HollandBIO membership (€562\,-/year)\, which besides access to the network & events\, offers many more advantages. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/dutch-biotech-event-2023/
LOCATION:Inn Style\, Herenweg 55\, Maarssen\, 3602 AN\, Netherlands
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T140000
DTEND;TZID=Europe/Brussels:20230627T160000
DTSTAMP:20260808T013912
CREATED:20230516T093527Z
LAST-MODIFIED:20230517T184028Z
UID:6244-1687874400-1687881600@www.europabio.org
SUMMARY:Reflection seminar and closing party around the EU presidency
DESCRIPTION:On June 27\, a Life Science conference is arranged for EU parliamentarians during Sweden’s EU presidency. \n\n\n\nDirectly after the official conference\, The Royal Academy of Engineering Sciences (IVA) and SwedenBIO invites the public to a seminar with the spotlight on how the suggested EU legislations may affect the life science industry. With examples from the Swedish life science arena\, we show the importance of intellectual property and data protection in the journey from academic research to products and therapies for patients. \n\n\n\nAfterward\, a networking reception is organized by the united life science industry organisations. With drinks\, snacks\, and key speakers\, we ensure that the end of the presidency marks the start of an even stronger united life science industry in Sweden and beyond. \n\n\n\n\nMore details
URL:https://www.europabio.org/event/reflection-seminar-and-closing-party-around-the-eu-presidency/
LOCATION:IVA Conference Center\, Grev Turegatan 15\, Stockholm\, Sweden
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230616T083000
DTEND;TZID=Europe/Brussels:20230616T100000
DTSTAMP:20260808T013912
CREATED:20230524T085454Z
LAST-MODIFIED:20230524T142847Z
UID:6326-1686904200-1686909600@www.europabio.org
SUMMARY:GREEK BIOPHARMA INNOVATION: Your changing world with the new EU Pharma Legislation
DESCRIPTION:Chairperson: Claire Skentelbery\, Director General EuropaBio \n\n\n\nParticipants: \n\n\n\nKostas Papagiannis Country President & Managing Director Novartis Greece \n\n\n\nHardy Rideout Anacalypsis Therapeutics \n\n\n\nGeorge Drakakis CEO PurposefulEU pharma legislation is going to change your business. What you make\, where and how you sell it\, and whether your business model is even viable.The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients\, the legislation proposals reduce data protection\, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval.Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, those seeking scale up investment\, clinical trials and companies going to market\, often for the first time.This session/panel\, chaired by EuropaBio\, presents the key impacts points for biotechnology innovation within Greece\, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/greek-biopharma-innovation-your-changing-world-with-the-new-eu-pharma-legislation/
LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230615T080000
DTEND;TZID=Europe/Brussels:20230617T180000
DTSTAMP:20260808T013912
CREATED:20230516T094713Z
LAST-MODIFIED:20230516T104047Z
UID:6258-1686816000-1687024800@www.europabio.org
SUMMARY:3rd Hellenic Biocluster Forum
DESCRIPTION:The Hellenic BioCluster is organizing its 3rd Forum on the subject of “Supporting disruptive innovation to maximize the economic and social impact of the bio-industry sector”\, scheduled to be held between 15 – 17 June 2023 at Megaron Athens International Conference Centre\, Athens\, Greece. \n\n\n\nThe 3rd HBio Forum features a 3-day\, cutting-edge programme with inspiring speakers from across the globe\, all experts in disruptive innovation\, with the aim to connect the global biotech innovation community under the sunny Athens skies. During the Forum B2B meeting opportunities will be provided between attendees and sponsors/exhibitors. \n\n\n\nThe 3rd HBio Forum will also include targeted panels of industry experts\, mentors and life sciences professionals to discuss hot topics related to investment such as raising capital and achieving success\, followed by a Pitching Competition. \n\n\n\n\nMore Details
URL:https://www.europabio.org/event/3rd-hellenic-biocluster-forum/
LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230601T100000
DTEND;TZID=Europe/Brussels:20230601T190000
DTSTAMP:20260808T013912
CREATED:20230321T205822Z
LAST-MODIFIED:20230321T210149Z
UID:6071-1685613600-1685646000@www.europabio.org
SUMMARY:KNOWLEDGE FOR GROWTH 2023
DESCRIPTION:Knowledge for Growth is Europe’s finest life sciences conference.For the first time the event will take place in Antwerp.\n\n\n\nThe conference features an exciting programme providing vital insight into the global life sciences’ landscape\, one-to-one partnering\, a trade fair and more! \n\n\n\nLEARN. CONNECT. DISCOVER.\n\n\n\nThe cream of the Belgian life sciences community attends flanders.bio’s annual Knowledge for Growth business conference\, attracting decision makers from biotech\, pharma and medtech\, agricultural and chemical industry as well as investors\, universities\, top-notch research institutes\, policymakers and competence providers. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/knowledge-for-growth-2023/
LOCATION:Flanders Meeting & Convention Center Antwerp\, Koningin Astridplein 26\, Antwerp\, 2018\, Belgium
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230526T100000
DTEND;TZID=Europe/Brussels:20230526T120000
DTSTAMP:20260808T013912
CREATED:20230523T140433Z
LAST-MODIFIED:20230523T141004Z
UID:6304-1685095200-1685102400@www.europabio.org
SUMMARY:ESAB-SusChem Webinar Sustainable Chemistry
DESCRIPTION:The European Society of Applied Biocatalysis (ESAB) and the European Technology Platform for Sustainable Chemistry (SUSCHEM) will held a Webinar on Sustainable Chemistry\, chaired by Pablo Domínguez de María (Sustainable Momentum SL\, ESAB Working Group Sustainable Chemistry\, SusChem Management Team) and Andrés R Alcántara (Complutense Univ of Madrid\, ESAB Working Group Sustainable Chemistry\, SusChem Board). \n\n\n\nPROGRAMME \n\n\n\n10:00 -10:30. MSc Irantzu Garmendia Aguirre\, Project Officer Safe and Sustainable by Design (SSbD)\, European Commission\, Directorate General Joint Research Centre\, Ispra\, Italy.Title: EC Recommendation for Safe and Sustainable by Design (SSbD) Chemicals Materials: scientific assessment framework policy context. \n\n\n\n10:30- 11:00. Prof. Dr. Dunming Zhu\, Tianjin Institute of Industrial Biotechnology\, Chinese Academy of Sciences\, Tianjin\, China.Title: Biocatalytic Synthesis of High Value Chemicals from Simple and/or Renewable Starting Materials. \n\n\n\n11:00-11:30. Dr. Fabrice Gallou\, Novartis Distinguished Scientist-Director Science & Technology Chemical Development\, Novartis\, Basel\, Switzerland.Title: Sustainability as a driver for innovation. \n\n\n\n11:30- 12:00. Prof. Dr. Dean Brady\, Molecular Sciences Institute\, School of Chemistry\, University of the Witwatersrand\, Johannesburg\, South Africa.Title: Biocatalysis in the synthesis of amines and amides. \n\n\n\n\nMore information here
URL:https://www.europabio.org/event/esab-suschem-webinar-sustainable-chemistry/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230517T160000
DTEND;TZID=Europe/Brussels:20230517T163000
DTSTAMP:20260808T013912
CREATED:20230516T082719Z
LAST-MODIFIED:20230516T082807Z
UID:6226-1684339200-1684341000@www.europabio.org
SUMMARY:EU Healthcare and Pharmaceutical Policy in 2023: What You Need to Know
DESCRIPTION:From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension\, the challenges in EU healthcare and pharmaceutical policy are ever-evolving. Plus\, with the implementation of critical files\, such as the European Health Data Space (EHDS) and the Substances of Human Origin (SoHo) regulation\, it’s vital for organizations in this market to stay up-to-date with the latest policy and regulatory developments. \n\n\n\nTune in on May 17 at 4 pm CEST | 10 am EDT for a 30-minute recorded webinar that will delve into the latest updates in legislation and regulation that are shaping the future of healthcare\, pharmaceutical\, and medical device industries in Europe to help you navigate the next steps in this policy landscape. \n\n\n\nExperts will discuss: \n\n\n\n\nThe ongoing revision of EU pharmaceutical legislation\n\n\n\nTackling critical supply issues in pharmaceuticals and medical devices\n\n\n\nThe impact of the Medical Device Regulation transition period extension\n\n\n\nProposed and upcoming critical files you should be monitoring\n\n\n\nThe future of EU healthcare policy in 2023 and beyond\n\n\n\n\nFeatured speakers: \n\n\n\n\nAdrien Samson\, healthcare policy & public affairs senior manager\, EuropaBio\n\n\n\nJelle Verheij\, policy analyst – health and pharmaceuticals policy\, EU Issue Tracker\n\n\n\nModerator: Geraint Edwards\, managing director of FiscalNote Brussels\n\n\n\n\n\nMore Details
URL:https://www.europabio.org/event/eu-healthcare-and-pharmaceutical-policy-in-2023-what-you-need-to-know/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/General-Promo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230424T100000
DTEND;TZID=Europe/Brussels:20230425T190000
DTSTAMP:20260808T013912
CREATED:20230111T144716Z
LAST-MODIFIED:20230111T144717Z
UID:5648-1682330400-1682449200@www.europabio.org
SUMMARY:Swiss Biotech Day 2023
DESCRIPTION:The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022\, the conference demonstrated the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1\,100 participants across the globe. \n\n\n\nIn 2023\, the Swiss Biotech Day will again offer high-level experts from the life science industry the space to network\, discuss and discover trends in R&D\, manufacturing\, data management\, artificial intelligence and innovative financing over one and a half days. In addition\, international biotech delegations can take part in the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments\, public-private partnerships\, research and development collaborations and exchange of talent.  \n\n\n\nWe hope to see you in Basel on April 24-25\, 2023 in person again. \n\n\n\nWhat to expect: \n\n\n\n\nMeet 1.000+ senior experts from the life science industry\n\n\n\n70+ exhibitors and global village with international delegations from all over the world\n\n\n\nSwiss Biotech Success Stories Awards\n\n\n\nInnovative biotech start-ups and medium-sized biotech companies\n\n\n\nThematically focused panel discussions\n\n\n\nSwiss Biotech Report 2023\n\n\n\nPre-scheduled one-to-one partnering meetings\n\n\n\nGeneral Assembly of the Swiss Biotech Association\n\n\n\n\n\nMore information
URL:https://www.europabio.org/event/swiss-biotech-day-2023/
LOCATION:Congress Center Basel\, Messeplatz 21\, Basel\, 4058\, Switzerland
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T150000
DTEND;TZID=Europe/Brussels:20230418T160000
DTSTAMP:20260808T013912
CREATED:20230124T170639Z
LAST-MODIFIED:20230406T134218Z
UID:5708-1681830000-1681833600@www.europabio.org
SUMMARY:Development of Orphan Biologics: Challenges and Opportunities
DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/
LOCATION:Catalent
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T100000
DTEND;TZID=Europe/Brussels:20230419T190000
DTSTAMP:20260808T013912
CREATED:20230110T150742Z
LAST-MODIFIED:20230110T151000Z
UID:5629-1681812000-1681930800@www.europabio.org
SUMMARY:CEBioForum 2023
DESCRIPTION:CEBioForum is a brand that has been creating a business environment related to biotechnology for over 20 years\, organizing the most important event of this type in the industry\, dedicated to the development of biotechnology in Poland and Europe \n\n\n\nCEBioForum 2023 will take place on April 18-19 in Warsaw \n\n\n\nBecause we strongly believe that networking is the basis for building lasting business relationships\, CEBioForum 2023 is held only face-to-face\, giving you a chance to make new connections with business partners\, scientists and decision makers from the government\, who contribute to biotech development in Poland and other CEE countries. \n\n\n\nCEBioForum 2023 is more then discussion panels\, networking and the opportunity to present your company. During the conference banquete\, we will honor outstanding people and companies with CEBioForum Awards 2023. \n\n\n\nSo save the date 18-19th of April and be with us in Warsaw at CEBioForum 2023. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/cebioforum-2023/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230328T100000
DTEND;TZID=Europe/Brussels:20230329T190000
DTSTAMP:20260808T013912
CREATED:20230320T155641Z
LAST-MODIFIED:20230320T155643Z
UID:6060-1679997600-1680116400@www.europabio.org
SUMMARY:German Biotech Days 2023
DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2023 (Deutsche Biotechnologietage\, DBT)\, will take place on March 28th and 29th in Wiesbaden. The event is the national forum for the German biotechnology industry. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. The two-day program highlights the diverse fields of application and the potential of biotechnology\, from health research to the bioeconomy. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2023 is Technologieland Hessen from Wiesbaden\, and we were able to win Infectognostics Forschungscampus Jena as another partner region. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/german-biotech-days-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230214T080000
DTEND;TZID=Europe/Brussels:20230215T170000
DTSTAMP:20260808T013912
CREATED:20230125T090903Z
LAST-MODIFIED:20230125T090904Z
UID:5720-1676361600-1676480400@www.europabio.org
SUMMARY:CLIB International Conference CIC2023
DESCRIPTION:From 14 to 15 February 2023\, the CLIB International Conference will take place in Düsseldorf\, Germany\, organised by CLIB – Cluster industrial biotechnology. Under the title ” Setting sail for industrial implementation” different sessions will debate how biotechnology help achieve the climate and sustainability goals. On the first day of the CIC2023\, the focus will be on levers in this monumental transformation\, highlighting where biotechnology can really make a difference: to harness sustainable resources\, to enable innovative processes\, and ultimately to close the carbon cycle. \n\n\n\nOn the second day\, CIC2023 will host the FARMŸNG satellite event\, focusing on zero-waste biorefineries. After inputs from this CBE JU flagship\, which is constructing the first-of-a-kind vertical large-scale insect farm\, other speakers will expand the scope towards other value chains\, discussing how zero-waste biorefineries can be planned\, built\, and sustainably supplied with feedstock\, all the while closing resource loops. A final keynote will focus on investing in scale-up projects and a holistic view on sustainability. \n\n\n\nAbout 200 participants are expected\, with representatives from industry\, a large number of national and international SMEs\, research institutions and stakeholders from politics and associations. In recent years\, the CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy. \n\n\n\nAbout CIC – CLIB International Conference \n\n\n\nThis is the annual international conference of the Cluster Industrial Biotechnology\, initiated in 2009 and now in its 13th edition. The CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy\, each year kicking off the biotech and bioeconomy conference circle early in the year. It has about 200 participants\, with representatives from industry\, a large number of national and international SMEs\, research institutions\, and stakeholders from politics and associations. \n\n\n\nAbout CLIB – Cluster Industrial Biotechnology \n\n\n\nCLIB (Cluster Industrial Biotechnology) is an international open innovation cluster of large companies\, SMEs\, academic institutes\, and universities\, as well as other stakeholders active in biotechnology and the circular bioeconomy as a whole. The cluster comprises over 100 members with a share of about 25 % international members. The overall goal of CLIB is to network stakeholders along and across value chains and to identify new opportunities for innovation\, projects\, and business. Through this\, the cluster develops cross-sectoral biotechnological solutions for sustainable processes and products. Pertinent project areas are identified by the CLIB team in conjunction with members in an iterative process. CLIB is a non-profit association\, with its members shaping the cluster’s interests and activities.
URL:https://www.europabio.org/event/clib-international-conference-cic2023/
LOCATION:Lindner Congress Hotel Düsseldorf\, Lütticher Str. 130\, Düsseldorf\, 40547\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/CIC2023-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230131T090000
DTEND;TZID=Europe/Brussels:20230131T123000
DTSTAMP:20260808T013912
CREATED:20230125T152351Z
LAST-MODIFIED:20230125T154606Z
UID:5741-1675155600-1675168200@www.europabio.org
SUMMARY:EIC – EMA Info Day: Regulatory support for the development of innovative medicines and technologies
DESCRIPTION:Join this online Info Day and discover the wide range of support services that the European Medicines Agency (EMA) provides to researchers and SMEs in the pharmaceutical and med-tech sectors. \n\n\n\nThe European Innovation Council (EIC)  and the European Medicine Agency (EMA) invite you to attend the EIC-EMA Info Day on January 31\, 2023 to hear about the wide range of support services provided by EMA to researchers and SMEs active in research and innovation in the pharmaceutical and med-tech sectors.   \n\n\n\nDuring the online Info Day\, you will learn on how to engage with EMA at different development milestones\, and on the range of EMA support services including those targeting gene and cell therapies\, and orphan medicines. You will also hear about the benefits to apply to the Innovation Task Force (ITF) services\, PRIME and Scientific Advice as well as practical details on how to prepare and submit applications. Moreover\, you will hear real examples of advice given through these services and will testimonials from academic researchers and companies funded by the EIC Pathfinder and Accelerator programmes on their experience with EMA services.  \n\n\n\nEIC grantees and future EIC applicants are strongly encouraged to participate. The event is also open to researchers and SMEs funded by other EU programmes.   \n\n\n\nThis event is relevant if:   \n\n\n\n\nYou are you an innovator in the health-tech sector funded by the EIC or other EU programmes. \n\n\n\nYou are in the early development stage of a medical technology or pharmaceutical\, and have not considered regulatory aspects of your innovation and support from authorities.  \n\n\n\nYour medical technology or pharmaceutical development is more advanced and you want to learn how to best apply to European Medicines Agency (EMA) services such as PRIME or Scientific Advice. \n\n\n\n\n\nMore information
URL:https://www.europabio.org/event/eic-ema-info-day-regulatory-support-for-the-development-of-innovative-medicines-and-technologies/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-3-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230127T100000
DTEND;TZID=Europe/Brussels:20230127T120000
DTSTAMP:20260808T013912
CREATED:20230128T220033Z
LAST-MODIFIED:20230128T220327Z
UID:5768-1674813600-1674820800@www.europabio.org
SUMMARY:ESAB Webinar: Advances in the Analysis of Enzymatic Reactions
DESCRIPTION:PROGRAMME \n\n\n\n10:00 – Prof. Dr. Andrew J. deMello\, Institute for Chemical and Bioengineering\,Department of Chemistry and Applied Biosciences\, ETH Zürich\, CH 8093 Zurich\,Switzerland \n\n\n\n10:30 – Prof. Dr. Aurelio Hidalgo\, Universidad Autonoma de Madrid\, Center for Molecular Biology “Severo Ochoa“\, 28049-Madrid\, Spain \n\n\n\n11:00 – Prof. Dr. Gerhard K.E. Scriba\, Friedrich Schiller University\, Department of Pharmaceutical Chemistry\, Jena\, Germany \n\n\n\n11:30 – Dr. Neil MacKinnon\, Principal Investigator\, NMR Spectroscopy for Metabolomics and Signalling\, Institute of Microstructure Technology\, Karlsruhe Institute of Technology\, Campus North\, 76344 Eggenstein-Leopoldshafen\, Germany \n\n\n\n  \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/esab-webinar-advances-in-the-analysis-of-enzymatic-reactions/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/2023-01-26-16_14_23-.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221206T090000
DTEND;TZID=Europe/Brussels:20221207T180000
DTSTAMP:20260808T013912
CREATED:20221116T144814Z
LAST-MODIFIED:20221116T145138Z
UID:5525-1670317200-1670436000@www.europabio.org
SUMMARY:17th European Bioplastics Conference
DESCRIPTION:The European Bioplastics Conference is Europe’s leading business and discussion forum within the global bioplastics sector. More and more brands and manufacturers are embracing the potential of biopolymers\, and policy makers are increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries. Now is the time to put bioplastics at the top of the agenda of a bio-based circular economy in Europe and beyond. \n\n\n\nThe registration for the 17th European Bioplastics Conference is now open and we are excited to welcome you on 6/7 December 2022 in Berlin or online.   \n\n\n\nThe hybrid format of this year’s event will allow you to join either in person at the Maritim proArte Hotel Berlin or comfortably log-in from your home base. Both of which offer unique networking opportunities  \n\n\n\nOf course\, we will also have an excellent exhibition on- and offline. Just choose the right type of booth to give your company visibility at the conference.  \n\n\n\n\nMore details
URL:https://www.europabio.org/event/17th-european-bioplastics-conference/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221006T090000
DTEND;TZID=Europe/Brussels:20221006T180000
DTSTAMP:20260808T013912
CREATED:20220524T095238Z
LAST-MODIFIED:20220524T095511Z
UID:4755-1665046800-1665079200@www.europabio.org
SUMMARY:LignoValue Pilot Launch & Biorizon Networking Event 
DESCRIPTION:Get informed about the latest progress in the field of biobased aromatics\, and join the pre-arranged\, bilateral matchmaking sessions!  \n\n\n\nOn 6 October 2022\, Shared Research Center Biorizon & VITO’s LignoValue Pilot Plant will host a live networking event at VITO in Mol\, Flanders.\n\n\n\nMajor industrial players\, small to medium‑sized enterprises\, and research and technology organisations from all over the world will join Biorizon to discuss the latest progress in the field of bio-aromatics and to elaborate on opportunities to accelerate biobased business together. Over the past years\, this has evolved into a must-attend event for anyone who’s interested in renewable aromatics. Last edition attracted 305 participants from 28 countries.Program live event – 6 October: \n\n\n\nBus visit to the impressive LignoValue Pilot Plant at VITO in Mol\, Flanders.Live networkingFormal launch of the LignoValue Pilot Plant & a brief update by Biorizon.\n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/lignovalue-pilot-launch-biorizon-networking-event/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-Website-1.png
END:VEVENT
END:VCALENDAR